Eli Lilly and Incyte’s atopic dermatitis drug received extended supplemental New Drug Application (NDA) review by the U.S. Food and Drug Administration (FDA) for baricitinib, a drug therapy intended for patients with moderate-to-severe conditions. The extension came after new data was submitted by Eli Lilly, per the FDA requests for more information, for longer review time. Baricitinib, originally developed by Incyte before licensing to Eli Lilly, is an oral Janus Kinase (JAK) inhibitor. “We remain confident in baricitinib and believe it has the potential to be an effective new treatment option for these patients,” stated Senior VP and President of Lilly Bio-Medicines, Ilya Yuffa.
Read more here.
More on: Medical Translation News Regulatory